Primary effusion lymphoma (PEL) harbors consistent infection by human herpesvirus-8, preferentially develops in immuno-
Introduction
Primary effusion lymphoma (PEL), otherwise termed body cavity based lymphoma, is a peculiar type of B cell non-Hodgkin lymphoma (NHL) that has been recently recognized as an individual clinico-pathologic category based on the consistent infection of the tumor clone by human herpesvirus type-8 (HHV-8) and the distinctiveness of its clinical and biologic features.
1-3 PEL preferentially develops in immunodeficient patients, including both HIV-positive individuals and posttransplant patients, and displays a marked preference for liquid growth in the serous body cavities. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The basic pathologic feature of PEL is a net predilection for diffuse spreading along the serous membranes without infiltrative or destructive growth patterns. 2 Although immunogenotypic studies have confirmed that PEL belongs in all cases to the B cell lineage, Correspondence: G Gaidano, Division of Internal Medicine, Department of Medical Sciences, Amedeo Avogadro University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy; Fax 39 0321 620-421 *These authors contributed equally to this manuscript Received 13 August 1999; accepted 7 October 1999 the overwhelming majority of cases exhibit a non-B, non-T (ie indeterminate) phenotype, lacking expression of surface immunoglobulins and common B cell associated antigens. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Recently, the histogenesis of PEL has been the focus of intense research. It is presently thought that PEL originates from a post-germinal center B cell which has undergone preterminal differentiation. In fact, PEL harbors somatic mutations of the immunoglobulin and BCL-6 genes. 11, 12 These mutations are acquired at the time of B cell transit through the germinal center (GC) and thus constitute a marker of GC and post-GC B cells. 11, 12 Further insight into the histogenesis of PEL has been gained from studies of CD138/syndecan-1, a member of the syndecan family that is expressed by multiple myeloma plasmacells. 13 The consistent expression of CD138/syndecan-1 by PEL cells has led to the notion that PEL reflects a postgerminal center, pre-terminally differentiated B cell.
To refine and corroborate the proposed model of PEL histogenesis, other markers specifically associated with the late stages of B cell differentiation need to be explored. Although such specific markers are rare, it has been proposed that concomitant expression of the tyrosine kinase receptor Met and of its ligand hepatocyte growth factor (HGF) is a feature of tumors of terminally differentiated B cells, namely multiple myeloma. 14, 15 Conversely Met/HGF co-expression is uncommon in other stages of B cell differentiation. 14, 15 The MET proto-oncogene encodes a tyrosine kinase cell surface receptor consisting of two disulfide-linked chains, the extracellular ␣ chain and the transmembrane ␤ chain. 16, 17 The ␤ chain contains the tyrosine kinase domain as well as sites for tyrosine autophosphorylation. The physiological function of Met is to serve as receptor for HGF. 16, 17 In normal tissues, Met is expressed primarily by epithelial cells and the endothelium. 16, 17 Among lymphoid tissues, expression of Met has been reported in GC centroblasts, some B cell lymphomas and, in association with HGF expression, in plasma cells of multiple myeloma. 14, 15, [18] [19] [20] HGF is a pleotropic cytokine of mesenchymal origin mainly produced by fibroblasts, macrophages and smooth muscle cells. 21, 22 HGF possesses both mitogenic and motogenic properties, since it promotes cell proliferation and angiogenesis and also causes spread of target epithelial cells. 21, 22 Because of its motogenic properties, HGF has also been designated 'scatter factor'. 21, 22 In lymphoid tissues, HGF production is mainly restricted to multiple myeloma plasma cells, which also express the HGF receptor Met. 14, 15 This study is aimed at refining the histogenesis and pathogenesis of PEL by investigating the expression status of Met and HGF in this type of lymphoma. We report that PEL cells consistently co-express Met and HGF, thus further corroborating the phenotypic similarities between PEL and neoplasms of terminally differentiated B cells. In addition, the functional 
Materials and methods

Patient samples and tumor cell lines
The present study was based on 13 samples of PEL, including nine cell lines and four primary specimens. For comparison, 34 other aggressive B cell NHL were also investigated, including 10 B-lineage diffuse large cell lymphomas (B-DLCL; six primary samples and four cell lines) and 24 Burkitt's lymphomas (BL; all cell lines). Primary tumor samples were obtained during routine diagnostic procedures at diagnosis prior to specific therapy. The diagnosis was based on morphologic, immunophenotypic and molecular criteria. In all cases tested, the proportion of neoplastic cells was Ͼ70%. The PEL cell lines forming the basis of this study were HBL-6, BC-1, BC-2, CRO-AP/2, CRO-AP/3, CRO-AP/5, BCBL-1, BC-3 and BCP-1. [23] [24] [25] [26] [27] [28] [29] [30] The detailed characterization of these cell lines has been reported previously. 31, 32 Seven out of nine PEL specimens were derived from HIV-infected patients, whereas two PEL samples (BC-3 and BCP-1) were derived from HIV-negative individuals. Among B cell NHL other than PEL, 9/34 cases (eight BL and one B-DLCL) were derived from HIV-positive patients, whereas the remaining cases were derived from HIV-negative individuals.
All cell lines were cultured in RPMI 1640 (GIBCO, Paisley, UK), supplemented with 10% heat-inactivated fetal bovine serum (GIBCO), 2 mM L-glutamine (GIBCO), 100 U/ml penicillin and 100 g/ml streptomycin (Irvine Scientific, Santa Ana, CA, USA) at 37°C in the presence of 5% CO 2 .
RT-PCR expression analysis of Met and HGF mRNA
Total RNA was isolated using a commercially available kit (Ultraspec-II RNA isolation system, Biotech Laboratories, Houston, TX, USA). cDNA was synthesized from 1 g RNA which had been incubated at 42°C for 45 min with 1 mM dNTPs, 2.5 M oligo (dT) 16 primer, 1 U/l RNase Inhibitor (Perkin Elmer, Nolwalk, CT, USA), 50 mM KCl, 10 mM TRISHCl (pH 8.3), 1.5 mM MgCl 2 and 2.5 U/l Moloney Murine Leukemia Virus Reverse Transcriptase (Perkin Elmer) in a final volume of 20 l. Reverse transcriptase was inactivated at 99°C for 5 min. The integrity of the cDNA samples was assessed by amplification of a 452 bp fragment of the human glyceraldehyde-3-phosphate dehydrogenase cDNA (G3PDH).
All the oligonucleotides used in this study were synthesized by the solid phase triester method on the basis of the published cDNA sequences of the Met, HGF and G3PDH genes. [33] [34] [35] The Met primer sequences were as follows: forward primer, 5Ј-CTTTGTTGGACAATGATGGC-3Ј; reverse primer, 5Ј-GGACCACACATCTGACTTGG-3Ј. The HGF primer sequences were as follows: forward primer 5Ј-CTCCCCATCGCCATCCCC-3Ј; reverse primer, 5Ј-CAC-CATGGCCTCGGCTGG-3Ј. The G3PDH primer were as follows: forward primer, 5Ј-ACCACAGTCCATGCCATCAC-3Ј; reverse primer, 5Ј-TCCACCACCCTGTTGCTGTA-3Ј. PCR was performed as follows: 5 l of cDNA was added to the reaction mixture containing 0.5 M of each primer, 50 mM KCl, 10 mM TRIS-HCl (pH 8.3), 1.5 mM MgCl 2 , 0.2 M dNTPs and 1 U of Taq-polymerase (Perkin Elmer) in a total volume of 25 l. The PCR was run for 25 (G3PDH and Met) or 35 (HGF) cycles on a Hybaid Omn-E thermocycler, with each cycle composed of 40 s at 94°C, 40 s at 55°C (Met and G3PDH) or 62°C (HGF), followed by 1 min of primer extension at 72°C. The expected PCR products of 452 bp (G3PDH), 518 bp (Met) or 749 bp (HGF) were visualized by ethidium bromide staining on a 2% agarose gel. Cytospin preparations of PEL cell lines and primary samples were fixed in acetone-chloroform at room temperature for 10 min before immunostaining with the anti-Met DO-24 MoAb. Immunocytochemistry was performed with the alkaline phosphatase (APAAP) method as described. 13 
FACS and immunocytochemical analysis of Met
Immunoprecipitation-Western blot analysis of Met
Cells (15 × 10 6 ) were washed with PBS and extracted with 400 l of DIM buffer (50 mM PIPES pH 7.4, 300 mM saccharose, 100 mM NaCl, 5 mM EGTA, 5 mM MgCl 2 , 100 M ZnCl 2 ) containing 1% Triton X-100, 1 mM ortho-vanadate, 1 mM phenylmethylsulfonyl fluoride, 20 g/ml aprotinin (Sigma, Bornem, Belgium), 50 g/ml leupeptin (Sigma) and 4 g/ml pepstatin (Sigma) (lysis buffer). After 20 min at 4°C, nuclei and insoluble material were removed by centrifugation. Then, supernatants were incubated with Pansorbin (Pierce, The Netherlands) for 1 h at 4°C. Met proteins were precipitated by incubation with the anti-Met MoAb DO-24 and rabbit-antimouse Ab coupled to Protein A-Sepharose (Amersham Pharmacia Biotech, Amersham, UK) at 4°C for 2 h. The immune complexes were washed twice with ice-cold DIM buffer and diluted in Laemmli sample buffer containing final concentrations of 62.5 mM TRIS-HCl (pH 6.8), 2% SDS, 20% glycerol, 100 mM 2-mercaptoethanol and 0.001% bromophenol blue. After boiling for 5 min, the samples were subjected to 8% SDS-PAGE under reducing conditions and transferred to nitrocellulose filters (Schleicher and Schuell, Dassel, Germany) which were saturated with 5% bovine serum albumine (BSA; Sigma) dissolved in TBS (20 mM TRIS-HCl, 137 mM NaCl, pH 7.6). Filters were then subjected to Western blotting with anti-Met MoAb DL-21, 36 followed by rabbit-antimouse Ab conjugated to horseradish peroxidase (Amersham Pharmacia Biotech). Filters were developed using the enhanced chemiluminescence system (ECL; Amersham Pharmacia Biotech).
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Quantification of HGF
Quantification of HGF was performed by both biologic (scatter assay) and immunologic (ELISA) assays. The scatter assay on Madin-Darby canine kidney (MDCK) cells (purchased from ATCC) was performed as previously described. 37 Cells were seeded at low density in 96-well plates, allowed to form colonies and exposed to PEL supernatants overnight. The scattering effect was monitored by light microscopy. One unit represents the minimun amount of factor dissociating Ͼ75% of the cell colonies. In our scatter assays, 1 unit of HGF corresponds to 0.2-0.3 ng. 38 ELISA for HGF was performed with a commercially available kit (Otsuka Assay Laboratories, Tokushima, Japan) according to the manufacturer's instructions.
Functional activity of Met and Met/HGF interactions in PEL
The functional activity of Met and the Met/HGF interactions were investigated in an in vitro tyrosine kinase (TK) assay and in a HGF stimulation assay, respectively. For the in vitro TK assay, 39 immunoprecipitated Met proteins were incubated in TK assay buffer (100 mM NaCl, 25 mM HEPES, 5 mM MnCl 2 , 5 mM MgCl 2 ), containing 10 Ci of ␥-32 P-ATP per sample. The reaction was stopped with ice-cold 50 mM EDTA in TBS. After boiling for 5 min, the samples were subjected to 8% SDS-PAGE. The gel was soaked with 1 M KOH for 1 h at 55°C to hydrolyse scrine/threonine phosphorylation and tyrosine kinase activity was recorded by autoradiography.
To analyze the activation of the Met receptor by HGF (HGF stimulation assay), 15 × 10 6 cells, made quiescent by serum consumption, were incubated for 10 min at 37°C in the presence or in the absence of 500 U of HGF, washed with PBS and solubilized in lysis buffer. Cleared cell extracts were immunoprecipitated with anti-Met MoAb and precipitates were resolved by 8% SDS-PAGE and transferred to nitrocellulose filters (Schleicher and Schuell). Filters were immunoblotted with an anti-phosphotyrosine MoAb (Upstate Biotechnology, Lake Placid, NY, USA), 40 and the appropriate secondary Ab and visualized with ECL system. After stripping, the same filters were resaturated, incubated with anti-Met MoAb DL-21 36 and revealed as above.
Results
Expression of Met and HGF mRNA in PEL
RT-PCR analysis of Met and HGF showed that 9/9 (100%) PEL cell lines co-expressed Met and HGF mRNA (Tables 1 and 2 ; RT-PCR analysis of Met and HGF expression in PEL. Total cytoplasmic RNA was subjected to retrotranscription and the obtained cDNA was amplified using pairs of primers specific for Met (a) and HGF (b). PEL cell lines are indicated at the top of each lane by their conventional denomination. The expected PCR products of 518 bp (Met) and 749 bp (HGF) were visualized by ethidium bromide staining on a 2% agarose gel. A negative control (NEG), represented by the Burkitt lymphoma cell line BL41, was included in each experiment.
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Leukemia 
Expression of Met protein in PEL
The expression of Met protein in PEL cells was analyzed by different independent techniques, including FACS analysis, immunocytochemistry and biochemistry, ie immunoprecipitation and Western blot. In FACS analysis and/or immunocytochemistry, Met expression scored positive in 9/9 (100%) PEL cell lines and 4/4 (100%) PEL primary specimens (Table 2 ; see Figure 2 for 
representative results). FACS analysis experiments defined that
Met was expressed at the surface of PEL cells.
To verify the biochemical identity of the Met expressed by PEL cells, we performed immunoprecipitation Western blot analysis in a representative panel of PEL cell lines (Table 2 and Figure 2 ). All PEL cell lines (n = 5) investigated by this technique scored positive for the presence of a Met specific signal. Because these experiments were performed in reducing conditions, which cause the dissociation of the ␣ and ␤ chains Met , ie the Met ␤ chain reacting with the MoAb utilized in these experiments. In addition to p145
Met , a weaker band of 170 kDa was also identified in 5/5 PEL cell lines. This band corresponds to the Met precursor p170
Met .
16,17
Quantification of HGF released by PEL HGF released by PEL was titrated in two independent assays. In a highly specific ELISA, all PEL supernatants tested (n = 8) were found to contain significant amounts of HGF, although the levels showed a 50-fold variation in the different PEL cell lines analyzed (Table 2 ). In particular, the BC-1 cell line released the highest level of HGF (15 ng/ml) whereas the CRO-AP/3 cell line released the lowest level (0.3 ng/ml). These data were confirmed in a biologic assay measuring HGF scatter activity (scatter assay) ( Table 2 ). All the cell lines which released HGF detectable in ELISA were found to produce and release HGF active in scattering MDCK cell colonies. Moreover, a strict quantitative correspondence was observed between the two assays. Because the scatter assay is based on the HGF ability to induce motility of target cells, positivity in this assay demonstrates that the HGF released by PEL cell lines is functionally active and is able to exert the motogenic activity characteristic of HGF.
Functional integrity of Met kinase receptor expressed by PEL
The ability of the Met receptor to undergo autophosphorylation after appropriate stimuli was investigated in two types of assays: the in vitro TK assay and the HGF stimulation assay. The in vitro TK assay explores the functional integrity of Met receptors isolated by immunoprecipitation, whereas the HGF stimulation assay investigates the in vivo phosphorylation status of Met on tyrosine residues before and after challenging intact cells with the cognate ligand HGF. Molecules phosphorylated in the in vitro TK assay were resolved in SDS-PAGE run under reducing conditions. All PEL cell lines investigated (n = 8) showed the presence of a phosphorylated band of 145 kDa corresponding to the Met ␤ chain (p145 Met ; Table 2 and Figure 3 ). This result points to the ability of Met to autophosphorylate and, therefore, to the functional integrity of the tyrosine kinase activity of the Met receptors isolated from PEL cells.
The HGF stimulation assay was performed in a representative PEL cell line (BC-2). Whereas the unstimulated BC-2 cell line expresses a low basal level of phosphorylated p145 Met , stimulation of BC-2 cells with HGF leads to a marked increase in tyrosine phosphorylation of p145 Met (Figure 3) , as revealed by blotting with anti-phosphotyrosine Ab. Incubation of the same blot with the anti-Met MoAb DL-21 showed that the expression levels of p145
Met remained stable before and after HGF stimulation of BC-2 cells, suggesting that the increase in the tyrosine phosphorylation signal was due to increase in the phosphorylation status of the Met receptor rather than to increase in the expression level of Met. Overall, these data indicate that the Met/HGF pathway in PEL cells is capable of signalling upon appropriate stimulation. 14,15 Among mature B cell neoplasms, co-expression of Met and HGF appears to be relatively specific for PEL and multiple myeloma, since other types of B cell NHL may occasionally express either Met or, more rarely, HGF but generally fail to co-express the two molecules (this study and Refs 14, 15, [18] [19] [20] . On these bases, it is conceivable that, in the B cell lineage, co-expression of Met and HGF is a selective feature of tumors corresponding to the pre-terminal or terminal stage of B cell differentiation.
Leukemia
Independent of histogenetic implications, the co-expression of Met and HGF by PEL cells may also reflect other biologic features of the tumor. In particular, it is notable that Met and HGF are also co-expressed by Kaposi's sarcoma spindle 41, 42 Because both PEL and Kaposi's sarcoma are characterized by tumor infection by HHV-8, 5 it is possible that Met/HGF co-expression observed in these two tumors may be related, directly or indirectly, to an effect induced by the virus. In this respect, it is notable that another ␥-herpesvirus, namely EBV, is able to affect Met regulation in B cells. 20 In fact, EBV infection induces Met expression in normal B-lymphocytes and, possibly, in B cell lymphomas other than PEL. In PEL, however, expression of Met occurs in both EBV-positive and EBV-negative samples ( Table 2 ), suggesting that EBV is not a primary regulator of Met in this lymphoma.
The Met and HGF expression by PEL bears potential implications for the pathogenesis of this lymphoma. Notably, Met/HGF co-expression is a consistent feature of PEL and the Met receptor appears to be basally phosphorylated in this lymphoma. In epithelial cells and cells of mesenchymal origin, the co-expression of Met and HGF activates the transforming ability of the receptor and causes the formation of an autocrine loop that stimulates tumorigenesis. 16, 17, 21, 22, 43, 44 In B cells, HGF-induced stimulation increases cell adhesion to extracellular matrix molecules and promotes migration. 19, 20 The putative involvement of Met and HGF in PEL pathogenesis is reinforced by the observation that fibroblasts of serous cavities produce significant amounts of HGF, 45 which, therefore, may be involved in both an autocrine and a paracrine fashion in PEL growth. Finally, since HGF has angiogenetic properties, 21, 22 the release of the cytokine by PEL cells adhering to the serosa may stimulate vessel formation. Indeed, growth of PEL cells in an animal model was accompanied by a marked degree of vascularization. 27 Similarly, autoptic studies of PEL patients have revealed that angiogenesis is a feature of serous cavities invaded by PEL cells (our unpublished observation).
The observation that concomitant expression of Met and HGF is frequent in PEL, whereas, with the exception of multiple myeloma, is extremely uncommon in other hematological malignancies, prompts further investigations of the role of this cytokine-receptor pair in PEL. Because the Met/HGF loop is functionally intact in PEL cells, future studies with blocking agents directed against Met and/or HGF need to address the biologic relevance of these molecules in PEL mitogenesis, motogenesis and cell adhesion.
